Ann: Danny Sharp appointed Independent Non-Executive Director, page-22

The corporate side and share price recognition are so underwhelming here compared to the medical, clinical and market fundamentals.

SAB from CoH, Andersson on the CAB, Anderson Cancer Center, University of Chicago, Institut Pasteur de Lille, field leaders in Australia.

100% response rate, 29 different cancers, FTO, cardio, radio, diabetes, obesity, CoH pancreatic paper.

Stop giggling at one another about how clever you are and get some runs on the board from your own bat and attract some real talent to the Board and the register.

@tigers2008 sounds on the money to me. How do we end up with this person and being their third company after BOT and ALC. If RAC gets anywhere near what they should get then this person is getting mega bucks for nothing because there doesn't seem anything positive about this for RAC.

ALC listed for over 10 years, under water, 1.3B shares on issue. BOT listed for over 35 years, at the bottom of the Mariana Trench, 1.2B SOI, $30k of revenue. I do not want to be associated with these companies. I'll be voting against this appointment.